ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone Symposia on Epigenetics and Human Disease

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present an overview of its 2 clinical stage compounds (“ORY-1001”and “ORY-2001”) at the Keystone Symposia on Epigenetics and Human Disease being held January 29th- February 2nd, 2017 at the Sheraton Seattle Hotel in Seattle, Washington, USA.

Click here to see the full Press Release